However, neither of the treatment groups was associated with the reduction in MHD, whereas MHD at baseline was (M3: \(\beta\)= 0.29, 95% CI 0.46, 0.11
In the phase 2 trial, participants started at 4 mg without escalation experienced significantly more adverse events than those who began at 2 mg
If you want one ratio for the entire protocol, 3 mL (3.33 mg/mL) is the most versatile
Additionally, the combined data showed no difference in the relative proportions of , , and cells between treatment (Figure 3B)
In contrast, GPx2 focuses on the gut, acting as a barrier against oxidants from food, which is why its abundant in intestinal cells
[3] [12] Testing for B12 status should be based on symptoms or risk factors rather than routine screening, with healthcare professionals assessing individuals who may be at higher risk of deficiency